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Abstract
Background: It has been suggested that the single nucleotide polymorphism 309 (SNP309, T ->
G) in the promoter region of the MDM2 gene is important for tumor development; however, with
regards to breast cancer, inconsistent associations have been reported worldwide. It is speculated
that these conflicting results may have arisen due to different patient subgroups and ethnicities
studied. For the first time, this study explores the effect of the MDM2 SNP309 genotype on
Taiwanese breast cancer patients.
Methods: Genomic DNA was obtained from the whole blood of 124 breast cancer patients and
97 cancer-free healthy women living in Taiwan. MDM2 SNP309 genotyping was carried out by
restriction fragment length polymorphism (RFLP) assay. The multivariate logistic regression and the
Kaplan-Meier method were used for analyzing the risk association and significance of age at
diagnosis among different MDM2 SNP309 genotypes, respectively.
Results: Compared to the TT genotype, an increased risk association with breast cancer was
apparent for the GG genotype (OR = 3.05, 95% CI = 1.04 to 8.95), and for the TG genotype (OR
= 2.12, 95% CI = 0.90 to 5.00) after adjusting for age, cardiovascular disease/diabetes, oral
contraceptive usage, and body mass index, which exhibits significant difference between cases and
controls. Furthermore, the average ages at diagnosis for breast cancer patients were 53.6, 52 and
47 years for those harboring TT, TG and GG genotypes, respectively. A significant difference in
median age of onset for breast cancer between GG and TT+TG genotypes was obtained by the
log-rank test (p = 0.0067).
Conclusion: Findings based on the current sample size suggest that the MDM2 SNP309 GG
genotype may be associated with both the risk of breast cancer and an earlier age of onset in
Taiwanese women.
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Background
A functional single nucleotide polymorphism has been
identified at position 309 within the first intron of the
promoter region of the human MDM2 gene and hence
designated SNP 309 [1]. Conversion of the T allele to the
G allele in the region causes a higher affinity for the Sp1
transcription activator and subsequently enhances the
transcription of MDM2 gene. Over-expression of MDM2
oncoprotein may result in a higher risk of carcinogenesis
and accelerated tumorigenesis by negatively regulating
p53 tumor suppressor protein [2].
Supporting evidence for the hypothesis that MDM2
SNP309 influences tumor formation is derived from the
clinical outcomes obtained from different research
groups. The median age of cancer diagnosis was found to
be nine years younger in SNP309 carriers compared with
non-carriers in Li-Fraumeni syndrome patients, including
those with breast cancer (29 yrs v.s. 39 yrs, p = 0.01) [1].
MDM2 SN309 was further reported to accelerate sporadic
breast cancer formation in Caucasians women in a gen-
der-specific and hormone-dependent manner [3]. A simi-
lar observation was reported by analyzing a large cohort of
familial breast cancer cases in South-West Netherlands,
although the estrogen signaling and mutant BRCA1/2 or
CHECK 1100delC was not required [4]. On the other
hand, MDM2-SNP309 was reported to be associated with
early onset of breast and ovarian cancer among BRCA1/2
mutant carrier of Jewish-Ashkenazi descent [5]. Interest-
ingly, a recent report showed that in the Chinese popula-
tion, MDM2 SNP309 G allele increased the risk of
sporadic breast cancer, but the T allele was associated with
earlier onset [6]. On the contrary, a combined study of 11
related breast cancer reports worldwide showed no effect
of MDM2 SNP309 on the risk of breast cancer [7]. More-
over, a large pooled series of more than 5,000 cases from
five European studies within the Breast Cancer
Association Consortium (BCAC) also concluded that no
association could be found between MDM2 SNP309 and
breast cancer [8]. However, both large cohort-based stud-
ies were unable to exclude MDM2 SNP309 involvement
in breast cancer time of onset. Two very recent studies sep-
arately focusing on Indian women and Scottish Caucasian
women also suggested no detectable association between
MDM2 SNP309 and breast cancer, although this genetic
polymorphism was associated with high grade nodal pos-
itive breast cancer in the latter population [9,10]. Due to
conflicting findings, further elucidation of the role of
MDM2 SNP309 in the risk of breast cancer and its time of
onset as well as possible association with racial/ethnic
subgroups is necessary.
In this study, we adopted a hospital-based case-control
study to investigate the association between MDM2
SNP309 and onset of breast cancer in the female Taiwan-
ese population. The first reason for this study was that rel-
evant information on the effect of the MDM2 SNP309 on
the risk of breast cancer remains sparse for Asian popula-
tions, including Taiwanese. Secondly, given that MDM2
SNP309 may influence tumor development in the
selected patient subgroup, the regional epidemiological
study was highly relevant and should provide important
information from which to better understand the role of
MDM2 SNP309 on breast cancer formation.
Methods
Research subjects
The participants were domestic Taiwanese women from
Taipei City Hospital Ren Ai branch in Taipei, Taiwan. One
hundred and twenty-four patients with sporadic breast
cancers diagnosed by cancer specialists and 97 cancer-free
healthy adult volunteers signed the consent form and
filled out the structured questionnaire to participate this
study. Other clinically defined metabolic symptoms such
as cardiovascular diseases or diabetes were also inquired
from the study subjects since it has been reported that
these factors may be associated with breast cancer, includ-
ing in the Taiwanese population [11-13]. Institutional
review board (IRB) approval from National Yang-Ming
University (IRB number: 970048, see additional file 1)
was obtained for this study. The age range was 21 to 76
years (median 54 years) for breast cancer patients and 18
to 77 years (median 38 years) for healthy controls, respec-
tively. Both of them were randomly and consecutively
enrolled. Except MDM2 SNP309 genotyping, no other
genetic background related to cancer development was
obtained from all participants.
MDM2 SNP309 genotyping
The genomic DNA preparation was performed on col-
lected blood samples and the genotyping procedure was
carried following a previous report with only minor mod-
ifications [14]. In brief, the genomic DNA was extracted
from 200 μl of blood sample donated by the participants
using the Qiagen mini blood DNA extraction kit (Qiagen
Inc., Valencia, CA). The chromosome region containing
the MDM2 SNP 309 was amplified by polymerase chain
reaction using a pair of primers, namely F (5'-CGGGAGT-
TCAGGGTAAAGGT-3') and R (5'-AGCAAGTCGGTGCT-
TACCTG-3'). The PCR reaction consists of 100 ng of
genomic DNA, 0.2 μM primer, 200 μM dNTP, 1.5 mM
MgCl2, 20 mM Tris-HCl (PH 8.4), 50 mM KCl and one
unit of Platinum Taq DNA polymerase (Invitrogen,
Carlsbad, CA). The thermal cycler conditions were 94°C
for one minute; 40 cycles with denaturing at 94°C,
annealing at 58°C, and elongation at 72°C for 30 seconds
each; one cycle at 72°C for 10 min. For restriction frag-
ment length polymorphism (RFLP) analysis, 10–20 μl of
the amplified 352 bp fragment was digested with one unitBMC Cancer 2009, 9:13 http://www.biomedcentral.com/1471-2407/9/13
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MSPA1I restriction enzyme (New England Biolabs, Ips-
wich, MA) at 37°C in a water bath for 30–60 minutes. The
T/T, T/G and G/G genotypes were distinguished by
observing the presence of fragments with lengths of 233
bp/88 bp, 233 bp/187 bp/88 bp, and 187 bp/88 bp after
electrophoresis on a 3% ethidium bromide stained NuS-
ieve agarose gel. The genotypes were further confirmed by
direct sequencing of the PCR products by the Sequencing
Core Facility of National Yang-Ming University Genomic
Research Center (YMGC).
Statistical analysis
The genotype and allele frequency of MDM2 SNP309 was
tested for Hardy-Weinberg equilibrium using an on-line
public statistical tool http://www.genes.org.uk/software/
hardy-weinberg.shtml, and the statistical significance was
determined by χ2 test. Two-sample t tests and Chi-square
tests were used to explore the bivariate association
between the status of breast cancer and other covariates
for continuous and categorical variables, respectively. Risk
association between the genotypes and breast cancer
development was estimated by odds ratio (OR) and 95%
confidence intervals (CI) using multivariate logistic
regression analysis. The variables shown to be statistically
significant in the bivariate analysis were adjusted in the
multivariate analysis. Among the breast cancer cases, Kap-
lan-Meier curves and the log-rank test were used to com-
pare the median onset age between patients with GG and
those with TG+TT genotypes in MDM2 SNP309. All statis-
tical analyses were performed with Statistical Analysis Sys-
tem software (ver. 9.1; SAS Institute, Cary, NC).
Results
The breast cancer patients (n = 124) and healthy controls
(n = 97) were all native Taiwanese women. The character-
istics of the healthy controls and breast cancer patients,
including average ages, body mass index (BMI), breast-
feeding experience, with or without high calorie intake,
oral contraceptives usage, and history of cardiovascular
disease/diabetes were summarized in Table 1. Among
these characteristics, age, BMI, patients with cardiovascu-
lar diseases and diabetes, and oral contraceptives usage
were significantly different between cases and controls
after the statistical testing (see materials and methods).
These confounding factors were adjusted in multivariate
logistic regression analysis.
The genotype and allele frequencies of MDM2 SNP309
calculated from 124 breast cancer cases and 97 controls of
Taiwanese women were summarized in Table 2. Although
the genotype frequency of the controls conformed to the
Hardy-Weinberg equilibrium (χ2 = 2.63), the breast can-
cer cases and the combined cohort showed a statistically
significant difference between the observed and expected
frequencies of the MDM2 SNP309 genotypes (χ2 = 10.84
and 12.18, respectively). The frequencies of both hetero-
zygous and homozygous genotypes were higher for breast
cancer cases than for healthy controls (64.5% v.s. 58% for
TG, and 21% v.s. 16% for GG). This observation suggests
that the G allele in MDM2 SNP309 is associated with the
risk of breast cancer in Taiwanese women. Furthermore,
using SNP309TT as a reference, the age-adjusted odds
ratios (ORs) for the TG and GG genotypes were 2.24 (95%
CI, 0.97 to 5.19) and 3.40 (95% CI, 1.21 to 9.57), respec-
tively (Table 3). When the ORs were further adjusted for
Table 1: The general characteristics of breast cancer patients and healthy controls from Taiwanese women blood donors
Characteristics, n (%)a Cases Control p-valueb
Age (yrs)
Mean 53.3 38.7 < 0.0001
S.D. 9.62 15.2
Body mass index (BMI, kg/m2) 24.09 ± 4.2 21.66 ± 3.13 < 0.0001
Breastfeeding
Yes 53 (42.7) 33 (34) 0.2794
No 71 (57.3) 64 (66)
High calorie intake
Yes 34 (27.4) 31 (32) 0.2786
No 90 (72.6) 66 (68)
Cardiovascular disease/diabetes
Yes 42 (33.9) 15 (15.5) 0.0019
No 82 (66.1) 82 (84.5)
Oral contraceptive pills usage
Yes 31 (25) 11 (11.3) 0.0202
No 93 (75) 86 (88.7)
a. Cases: n = 124; controls: n = 97. The percentages were shown in the parentheses
b. Age and BMI were determined by two-sample t tests; breastfeeding, high calorie intake, cardiovascular disease/diabetes, and oral contraceptive 
drugs usage were determined by chi-square tests.BMC Cancer 2009, 9:13 http://www.biomedcentral.com/1471-2407/9/13
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age, BMI, cardiovascular diseases/diabetes, and oral con-
traceptives usage, they still showed a risk association of
GG (OR = 3.05, 95% CI = 1.04 to 8.95) and TG (OR =
2.12, 95% CI = 0.90 to 5.00) genotypes in breast cancer
cases (Table 3). Together, these data indicate that the
homozygous MDM2 SNP309 GG genotype may increase
the risk of breast cancer in Taiwanese women.
Among the breast cancer patients, the mean ages at diag-
nosis for the TT, TG and GG genotypes of MDM2 SNP309
were 53 (range 42–66), 51.5 (range 21–72) and 46.9
(range 30–64) years old, respectively. The survival analy-
sis using the Kaplan-Meier method showed that the onset
age of breast cancer in patients with GG genotypes and
TG+TT genotypes was significantly different (log-rank test,
p = 0.007, Figure 1). Therefore, current data suggest that
homozygous GG but not TG genotype of MDM2 SNP309
may also accelerate the incidence of breast cancer among
the female Taiwanese population.
Discussion
In this study, we found that MDM2 SNP309 was associ-
ated with the risk of breast cancer incidence as well as an
earlier onset of this disease in female Taiwanese popula-
tion (124 breast cancer cases). Compared to other reports,
such as the large-cohort studies of BCAC in Europeans
(5,191 cases) and in African-Americans and Caucasians in
North Carolina (2,037 cases) [8,15], or studies with rela-
tively smaller sample sizes in Japanese (557 cases), Chi-
nese (366 cases), British (351 cases), Germany (549
cases), Americans in Baltimore (294 cases), Turkish (223
cases), Indian (104 cases), and Scottish (299 cases)
[9,10,16-21], more cases from Taiwanese women are
expected to be assessed in the future. Nevertheless, our
result is consistent with the assumption that certain sub-
groups may be affected by this genetic background on
tumor development [8,18,22].
In addition to small sample size, this hospital-based case-
control study has several limitations. For instance, ages
and BMI of breast cancer participants were significantly
older and higher than that of the healthy controls in this
study. However, all of the samples were consecutive par-
ticipants who consented to be enrolled in this study, and
it was not possible to predict the genotype of MDM2
SNP309 among them. In addition, we adjusted these con-
founding factors in subsequent statistical analyses to min-
imize the potential biasing effects. Another limitation is
that other genetic factors, such as p53 or BRCA1/2 geno-
types have not been assessed in our study. Therefore, it
Table 2: MDM2 SNP309 genotype and allele frequencies of Taiwanese breast cancer cases and healthy controls
MDM2 SNP309a
Frequency Cases, n (%) Controls, n (%) Entire cohort n (%)b
Genotype
TT 18 (14.5) 25 (25.8) 43 (19.4)
TG 80 (64.5) 56 (57.7) 136 (61.7)
GG 26 (21) 16 (16.5) 42 (18.9)
TG+GG 106 (85.5) 72 (74.2) 179 (80.6)
Allele
T 0.468 0.541 0.498
G 0.532 0.459 0.502
aThe χ2 of cases, controls and entire cohort are 10.84, 2.63, and 12.18, respectively. Degree of freedom (d.f.) = 2
b Entire cohort is the sum of each genotype in breast cancer cases and healthy controls.
Table 3: The risk evaluation of MDM2 SNP309 genotypes on the development of breast cancer in Taiwanese women
SNP309a OR (95% CI)b p-value OR (95% CI)c p-value OR (95% CI)d p-value
TT 1 1 1
TG 1.98 (1.00 to 3.98) 0.05 2.24 (0.97 to 5.19) 0.06 2.12 (0.90 to 5.00) 0.08
GG 2.26 (0.95 to 5.38) 0.07 3.40 (1.21 to 9.57) 0.02 3.05 (1.04 to 8.95) 0.04
TG+GG 2.06 (1.05 to 4.06) 0.04 2.48 (1.10 to 5.60) 0.03 2.30 (1.00 to 5.30) 0.05
a The frequency of each genotype is referred to Table 2.
b The crude OR values.
c Age-adjusted OR values.
d These OR values are the results adjusted for age, BMI, cardiovascular disease/diabetes, and OCP (Oral Contraceptive Pill) usageBMC Cancer 2009, 9:13 http://www.biomedcentral.com/1471-2407/9/13
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cannot be ruled out that MDM2 SNP309 may combine
with these genetic factors to affect the development of
breast cancer in Taiwanese women. Indeed, Huang et al.
has found that an interaction between MDM2 SNP309
and mutant p53 is able to affect tumor behavior in spo-
radic oral squamous cell carcinomas in Taiwanese [23]. To
the best of our knowledge, a similar interaction has not
been studied in the cases of Taiwanese breast cancer yet.
Taken together, increased sample size and investigation of
other genetic factors will be important in better under-
standing the effects of MDM2 SNP309 on breast cancer
development in the Taiwanese population.
The association of metabolic syndromes and lifestyle to
breast cancer was also taken into account in our study.
High calorie diet usually leads to obesity, hyperglycemia,
hyperinsulinemia, diabetes mellitus and hypertension
[13,24]. Increase incidence of breast cancer in the Asian
population has in part paralleled the shift toward Western
dietary practices that cause the development of obesity
[25-27]. It has been reported that Taiwanese patients with
diabetes have higher risk of breast cancer mortality at all
ages [11]. Also, high dietary fat intake as well as usage of
oral contraceptives significantly increase the risk of breast
cancer in Taiwanese women [28,29]. On the contrary,
breast feeding may exert a protective effect in the Taiwan-
ese population [30]. In addition to the Taiwanese-based
studies, these potential factors in the risk assessment of
breast cancer have also been evaluated by other groups
worldwide [12,13,31-38]. Accordingly, the patients with
cardiovascular disease/diabetes and oral contraceptive
usage were adjusted for multivariate logistic regression
analysis since these factors exhibited significant differ-
ences among cases and controls by Chi-square tests. It will
be of interest to further investigate whether it is possible
for an interaction between MDM2 SNP309 and obesity-
associated metabolic syndromes to affect breast cancer by
assessing a larger Taiwanese population.
Association between MDM2 SNP309 GG genotype with earlier age onset of breast cancer cases in Taiwanese women Figure 1
Association between MDM2 SNP309 GG genotype with earlier age onset of breast cancer cases in Taiwanese 
women. The survival curve of GG genotype was compared with that of TG+TT genotype. The Y axis represented the cumu-
lative case-free survival rate against age at diagnosis. The statistical difference between two survival curves was evaluated by 
log-rank test.BMC Cancer 2009, 9:13 http://www.biomedcentral.com/1471-2407/9/13
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It is unknown whether the rate of the MDM2 SNP309 GG
genotype (21%) among Taiwanese breast cancer patients
is significantly different from other ethnic groups. When
we compared this frequency to other ethnic groups with
breast cancer, the results were as follows for the various
studied populations: Anglo-Saxon (16.8%), Chinese
(23.2%), Indian (30%), German (16%), Caucasian
(18.4%), African-American (0.6%), Jewish-Ashkenazi
(33%) and South-West Netherlands (14%)
[4,9,15,17,18]. This showed that the Taiwanese and the
Chinese patients exhibited most similar frequency of GG
genotype compared to other ethnic groups. Ma et al., have
reported that G allele of MDM2 SNP309 may be not
involved in the risk of breast cancer formation from
Jiangsu province in mainland China (OR = 0.92, 95% CI
= 0.62 to1.37) [18]. However, Lum et al. demonstrated
that the MDM2 SNP309 G allele increased risk in sporadic
breast cancer in a Chinese population from Shanghi city
[6]. Given that the main immigrants of Taiwan are from
mainland China, this implies that the effects of MDM2
SNP309 on the risk of breast cancer may be associated
with environmental discrepancy and confined to the
selected subgroups even in similar ethnicities.
Similar to the risk estimation, whether MDM2 SNP309 is
associated with an earlier age onset of breast cancer
remains controversial [1,4,17,18,39]. Using Kaplan-Meier
survival analysis, we found that breast cancer patients
with GG genotype were 5 to 6 years earlier in age at diag-
nosis compared to TT+TG genotype in Taiwanese women.
Such a result partially agrees with the report by Bond et al.,
which showed that GG women are associated with a 7-
year average earlier age of onset of breast cancer compared
with TT women [39]. However, whether such a relation-
ship is associated with the expression level of the estrogen
receptor is unknown from this study. On the other hand,
this observation conflicts to the report claiming that T
allele is essentially associated with earlier onset of breast
cancer in the Chinese population [6]. It is speculated that
MDM2 SNP309 may play a complex role in the time of
onset for breast cancer among various subgroups.
Taken together, this hospital-based case-control study
suggests that MDM2 SNP309 is associated with the risk of
breast cancer in Taiwanese women. Furthermore, the GG
genotype can accelerate the age at diagnosis compared to
the TT+TG genotype. The small sample size of this study
may limit the conclusion ascribed from our statistic
assessment. Nevertheless, smaller sample size has also
been reported in findings on the effects of MDM2 SNP309
on breast cancer and endometrial cancers [1,14]. A per-
spective study that is based on a larger sample size is nec-
essary, and it will be important to evaluate the interaction
between MDM2 SNP309 and other genetic backgrounds
to identify the significance of MDM2 SNP309 on the risk
and onset time of breast cancer in the Taiwanese popula-
tion.
Conclusion
Our data suggested that the homozygous MDM2
SNP309GG genotype simultaneously affected the risk and
the onset age of breast cancer in the Taiwanese popula-
tion. Given that several reports showed no association
between MDM2 SNP309 and the risk of breast cancer, our
findings suggest that such a polymorphism is possibly
dependent on various subgroups. A larger sample size is
expected to assess the association between MDM2
SNP309 and breast cancer incidence in Taiwanese women
in the future.
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